Hydroxychloroquine does not impair antibody response to 13‐valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus—A pilot study.

Pneumococcal pneumonia is an important cause of morbidity and mortality among patients with lupus erythematosus. Therefore, a vaccination against pneumococcal infections prior to the immunosuppressive therapy is strongly recommended in these patients. Antimalarials are the standard first‐line systemic therapy for cutaneous lupus erythematosus (CLE). However, as many as 50% of CLE patients can be recalcitrant to this treatment and may require more intense immunosuppressive management such as for example, methotrexate, mycophenolate mofetil or azathioprine. The main aim of the current study was to assess the immunogenicity of the pneumococcal conjugate vaccine (PCV) in patients with CLE receiving hydroxychloroquine (HCQ) for at least 6 months prior to the study entry. Twenty patients with CLE but not systemic lupus erythematosus (SLE) who were receiving HCQ and five age‐ and sex‐matched healthy volunteers were included in this study. All individuals were vaccinated with 13‐valent PCV. Levels of anti‐pneumococcal capsular polysaccharide (anti‐PCP) IgM and IgG antibodies were measured before and 6 weeks after vaccination. Anti‐PCP IgM and IgG levels increased significantly in both CLE and controls upon vaccination (p < 0.0001 and p < 0.05, respectively). Ninety‐five percentage of CLE patients and 80% of healthy volunteers achieved at least 2‐fold increase in levels of anti‐PCP IgG upon vaccination. Vaccination was good tolerated in both groups. The CLE activity score before vaccination was not modified thereafter. Hydroxychloroquine does not impair immune response to PCV13. The time period when patients with CLE are receiving HCQ could be used for immunization before more intense immunosuppressive therapy would be initiated. [ABSTRACT FROM AUTHOR]